Refine results

Molecule down arrow
Disease state down arrow
Phase down arrow
Status down arrow

Showing 14 results

CaDAnCe-101 | BGB-16673-101

CaDAnCe-101 | BGB-16673-101

BGB-16673 B-Cell Malignancies Phase 1, Phase 2 Recruiting
CELESTIAL-TN CLL | BGB-11417-301

CELESTIAL-TN CLL | BGB-11417-301

Sonrotoclax, Zanubrutinib CLL Phase 3 Active, not recruiting
BGB-11417-201

BGB-11417-201

Sonrotoclax MCL Phase 1, Phase 2 Active, not recruiting
BGB-11417-105

BGB-11417-105

Sonrotoclax MM Phase 1b, Phase 2 Recruiting
BGB-11417-103

BGB-11417-103

Sonrotoclax AML, MDS/MPN Phase 1, Phase 2 Recruiting
BGB-11417-102

BGB-11417-102

Sonrotoclax B-Cell Malignancies Phase 1 Active, not recruiting
BGB-11417-101

BGB-11417-101

Sonrotoclax, Zanubrutinib Mature B-Cell Malignancies Phase 1 Active, not recruiting
BGB-3111-215

BGB-3111-215

Zanubrutinib B-Cell Malignancies Phase 2 Completed

You are now leaving the website

This link is provided for information purposes only. You’ll be leaving beonemedaffairs.com and accessing a third-party website over which [BeOne Medicines | GmbH] has no control or influence.

This link will take you to a third-party website outside of beonemedaffairs.com.

[BeOne Medicines | GmbH] has no control over this website and makes no representations regarding its content or availability in your location. [BeOne Medicines | GmbH] declines any responsibility for third-party information, data usage policies, or personal data processing.

By proceeding, you acknowledge that you are part of the intended audience of the third-party website and confirm your compliance with applicable laws.

Do you want to leave beonemedaffairs.com

You are now leaving the the website beonemedaffairs.com and entering another BeOne website with different terms of use. Information included on this website may not be specific to your country. Click Continue to proceed